Small Cell Lung Cancer Treatment Landscape - 03/18/25 - Lung Cancer Living Room™ скачать в хорошем качестве

Small Cell Lung Cancer Treatment Landscape - 03/18/25 - Lung Cancer Living Room™

Small Cell Lung Cancer Treatment Landscape | The Lung Cancer Living Room (March 2025) In this vital episode of the Lung Cancer Living Room™, Danielle Hicks (Chief Patient Officer, GO2 for Lung Cancer) is joined by Dr. Carl Gay, Assistant Professor of Medical Oncology at MD Anderson Cancer Center, to walk us through the current and emerging treatment landscape for small cell lung cancer (SCLC). As Dr. Gay emphasizes early in the conversation, the only thing small cell and non-small cell lung cancers have in common is that they originate in the lung. Biologically, they are entirely different diseases — and that distinction is critical to understanding diagnosis, staging, and treatment decisions. This rich and hopeful discussion highlights how treatment for both limited-stage and extensive-stage SCLC is evolving, with breakthroughs in immunotherapy, bispecific T-cell engagers (BiTEs), and exciting new clinical trials changing the outlook for patients. Key Topics Covered: • The fundamental biological differences between small cell and non-small cell lung cancer • How staging is approached: limited-stage vs. extensive-stage small cell lung cancer • The critical role of brain MRI surveillance due to high rates of brain metastases • Standard first-line treatment: platinum-based chemotherapy and etoposide • The evolving use of maintenance immunotherapy (e.g., durvalumab in the ADRIATIC trial) after chemoradiation in limited-stage disease • A nuanced conversation about the role and limitations of surgery in limited-stage SCLC • The importance of early integration of palliative care, even alongside active treatment • The impact of immune checkpoint inhibitors in extensive-stage SCLC and why responses are limited to a small subset of patients • A deep dive into tarlatamab, a promising bispecific T-cell engager (BiTE) targeting DLL3, and its early success in treating relapsed SCLC • How tarlatamab is administered, its unique side effects, and why inpatient monitoring is initially required • The importance of peer support and patient community in navigating new therapies like tarlatamab • The ongoing debate and evolving practices around PCI (prophylactic cranial irradiation) in both limited- and extensive-stage SCLC • A compelling case for enrolling in clinical trials, including mentions of the ADRIATIC, IMpower133, CASPIAN, and DLL3-targeted tarlatamab trials This episode is a must-watch for anyone affected by small cell lung cancer—patients, caregivers, and providers alike—offering an honest and hopeful look at what's changing in the field and where we are headed next. 🟢 Stay up-to-date with new treatments, connect with support, and explore resources at go2.org/livingroom 🟢 Sign up for text message reminders! GO2 for Lung Cancer has launched a new text service to remind you that the Lung Cancer Living Room is that evening. We will send texts to those who opt-in. If you would like to receive these reminders, please opt-in by texting the word “LivingRoom” to 844-871-7558. If at any time you don’t want to receive these messages, text “STOP” and you will be removed from the distribution list. 00:00 Introduction 01:18 What is small cell lung cancer (SCLC)? 04:25 About brain metastases in SCLC 06:00 Treatment options for SCLC 08:32 Chemotherapy response in SCLC 10:49 Limited stage small cell lung cancer treatments 16:06 All about extensive stage SCLC 18:08 The importance of palliative care for pain management 21:58 Exciting new therapies (treatments) for SCLC 25:18 All about T-cell engager (TCE) therapies 29:20 Understanding the delivery of bispecific T-cell engager therapy 39:26 New understandings around prophylactic cranial radiation (PCI) 42:51 The importance of clinical trials 44:12 Conversations you should have with your healthcare provider 48:38 Most exciting things happening now in SCLC